M. Bunnage

发表

Getting pharmaceutical R&D back on target.

M. Bunnage, 2011, Nature chemical biology.

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

S. Knapp, J. Bradner, O. Fedorov, 2013, Cancer research.

Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists

Li Xing, Guoyun Bai, Atli Thorarensen, 2016, Scientific Reports.

The discovery of long acting β2-adrenoreceptor agonists

Alan Daniel Brown, Mark E. Bunnage, M. Bunnage, 2007 .

Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.

M. Bunnage, David A. Price, M. Trevethick, 2011, Bioorganic & medicinal chemistry letters.

Optimized glucuronidation of dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

M. Bunnage, David A. Price, M. Trevethick, 2011 .

Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance

S. Knapp, P. Biggin, O. Fedorov, 2015, Science Advances.

Applications of chemogenomic library screening in drug discovery

Lyn H. Jones, Mark E. Bunnage, M. Bunnage, 2017, Nature Reviews Drug Discovery.

Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.

S. Knapp, O. Fedorov, M. Bunnage, 2016, Journal of medicinal chemistry.

The oxide anion accelerated retro-diels-alder reaction.

M. Bunnage, K. Nicolaou, 1997, Chemistry.

Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.

M. Bunnage, David A. Price, A. Wood, 2011, Journal of medicinal chemistry.

Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1.

Kevin J. Gagnon, F. Maltais, P. Charifson, 2021, Journal of medicinal chemistry.

Fluorine in Drug Design: A Case Study with Fluoroanisoles

M. Bunnage, R. Denny, A. Narayanan, 2015, ChemMedChem.

Lead Diversification 2: application to P38, gMTP and lead compounds.

M. Bunnage, M. Bazin, T. Peakman, 2012, Bioorganic & medicinal chemistry letters.

Lead diversification. Application to existing drug molecules: mifepristone 1 and antalarmin 8.

M. Bunnage, Iñaki Morao, M. Bazin, 2012, Bioorganic & medicinal chemistry letters.

Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

M. Bunnage, David A. Price, A. Brown, 2010, Journal of medicinal chemistry.

Asymmetric synthesis of anti-(2S,3S)- and syn-(2R,3S)-diaminobutanoic acid.

M. Bunnage, S. Davies, Andrew D. Smith, 2003, Organic & biomolecular chemistry.

Asymmetric synthesis of the taxol and taxotère C-13 side chains

M. Bunnage, S. Davies, Christopher J. Goodwin, 1994 .

Asymmetric synthesis of the putative structure of (-)-oryzoxymycin.

M. Bunnage, P. Steel, D. Orton, 2003, Organic letters.

Total Synthesis of Balanol

M. Bunnage, K. Nicolaou, K. Koide, 1994 .

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.

M. Bunnage, K. Beaumont, D. Leahy, 2012, Bioorganic & medicinal chemistry.

Asymmetric Michael additions of homochiral magnesium amides

M. Bunnage, S. Davies, I. Walters, 1994 .

Asymmetric synthesis of homochiral syn- and anti-3-phenylisoserine derivatives: a practical strategy for the synthesis of the taxol C-13 side chain

M. Bunnage, S. Davies, Christopher J. Goodwin, 1993 .

Asymmetric Synthesis of Allophenylnorstatine

M. Bunnage, S. Davies, Christopher J. Goodwin, 1993 .

Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.

K C Nicolaou, S. Taylor, M. Bunnage, 1995, Chemistry & biology.

Asymmetric synthesis of the N-terminal component of microginin: (2S,3R)-3-amino-2-hydroxydecanoic acid, its (2R,3R)-epimer and (3R)-3-aminodecanoic acid

M. Bunnage, S. Davies, A. Burke, 1995 .

Total Synthesis of Brevetoxin A: Part 3: Construction of GHIJ and BCDE Ring Systems

P. A. Wallace, M. Bunnage, K. Nicolaou, 1999 .

Total Synthesis of Balanol and Designed Analogues

M. Bunnage, K. Nicolaou, K. Koide, 1995 .

An expeditious asymmetric synthesis of allophenylnorstatine

M. Bunnage, O. Ichihara, S. Davies, 1994 .

Acidic triazoles as soluble guanylate cyclase stimulators.

P. A. Bradley, M. Bunnage, Y. M. Fobian, 2011, Bioorganic & medicinal chemistry letters.

Kinetic resolution of tert-butyl (RS)-3-alkylcyclopentene-1-carboxylates for the synthesis of homochiral 3-alkyl-cispentacin and 3-alkyl-transpentacin derivatives.

M. Bunnage, S. Davies, Andrew D. Smith, 2004, Organic & biomolecular chemistry.

Asymmetric synthesis of the cis- and trans-stereoisomers of 4-aminopyrrolidine-3-carboxylic acid and 4-aminotetrahydrofuran-3-carboxylic acid.

M. Bunnage, S. Davies, Andrew D. Smith, 2004, Organic & biomolecular chemistry.

Asymmetric synthesis of (1R,2S,3R)-3-methylcispentacin and (1S,2S,3R)-3-methyltranspentacin by kinetic resolution of tert-butyl (+/-)-3-methylcyclopentene-1-carboxylate.

M. Bunnage, S. Davies, Andrew D. Smith, 2003, Organic and biomolecular chemistry.

Asymmetric Synthesis of the cis‐ and trans‐Stereoisomers of 4‐Aminopyrrolidine‐3‐carboxylic Acid and 4‐Aminotetrahydrofuran‐3‐carboxylic Acid.

M. Bunnage, S. Davies, Andrew D. Smith, 2005 .

Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains

S. Knapp, O. Fedorov, M. Bunnage, 2014, Journal of the American Chemical Society.

Asymmetric synthesis of β-amino-α-hydroxy acids via diastereoselective hydroxylation of homochiral β-amino enolates

M. Bunnage, S. Davies, A. N. Chernega, 1994 .

The promise and peril of chemical probes.

John P. Overington, Jian Jin, Matthieu Schapira, 2015, Nature chemical biology.

Total Synthesis of Brevetoxin A: Part 1: First Generation Strategy and Construction of BCD Ring System

P. A. Wallace, M. Bunnage, K. Nicolaou, 1999 .

(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells

Amber L. Couzens, A. Gingras, M. Bunnage, 2014, Proceedings of the National Academy of Sciences.

Erratum: The promise and peril of chemical probes (Nature Chemical Biology (2015) 11 (536-541))

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .

Know your target, know your molecule.

Mark E Bunnage, Erik C Hett, M. Bunnage, 2015, Nature chemical biology.

Donated chemical probes for open science

Anton Simeonov, Steve Hitchcock, Stefan Laufer, 2018, eLife.

Target validation using chemical probes.

Mark E Bunnage, M. Bunnage, Lyn H Jones, 2013, Nature chemical biology.

Small molecule modulation of stem cells in regenerative medicine: recent applications and future direction

M. Bunnage, P. Fish, T. Allsopp, 2010 .

Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit

S. Knapp, M. Bunnage, P. Fish, 2012, Journal of medicinal chemistry.

TOTAL SYNTHESIS OF BREVETOXIN A : PART 2 : SECOND GENERATION STRATEGY AND CONSTRUCTION OF EFGH MODEL SYSTEM

P. A. Wallace, M. Bunnage, K. Nicolaou, 1999 .

Inhibition of protein kinases by balanol: specificity within the serine/threonine protein kinase subfamily.

S. Taylor, M. Bunnage, K. Nicolaou, 1999, Molecular pharmacology.

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.

D. Altshuler, M. Bunnage, D. Gipson, 2023, The New England journal of medicine.

The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists.

Mark E Bunnage, M. Bunnage, David A. Price, 2008, Bioorganic & medicinal chemistry letters.

Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase.

K C Nicolaou, N. Xuong, S. Taylor, 1999, Biochemistry.

Total Synthesis of Balanol and Designed Analogues.

M. Bunnage, K. Nicolaou, K. Koide, 1996 .

Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor.

D. J. Bull, M. Bunnage, D. Owen, 2010, Bioorganic & medicinal chemistry letters.

Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.

M. Bunnage, K. Beaumont, J. Blagg, 2007, Journal of medicinal chemistry.

The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.

Mark E Bunnage, M. Bunnage, David A. Price, 2007, Bioorganic & medicinal chemistry letters.

Preclinical target validation using patient-derived cells

Arthur S Slutsky, J. Isaac, B. Pollock, 2015, Nature Reviews Drug Discovery.

Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

Mark E Bunnage, Samantha J Hughes, Peter G. Dodd, 2011, Journal of medicinal chemistry.

SAR mining and its application to the design of TRPA1 antagonists

Sarah Elizabeth Skerratt, James Edward John Mills, Alan Daniel Brown, 2012 .

Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.

M. Bunnage, J. Mathias, A. Wood, 2008, Bioorganic & medicinal chemistry letters.

Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells.

M. Bunnage, J. Telliez, Betsy S. Pierce, 2017, ACS chemical biology.

Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.

M. Bunnage, J. Kanter, L. G. Paloma, 1995, Chemistry and Biology.

TAFIa inhibitors in the treatment of thrombosis.

M. Bunnage, D. Owen, 2008, Current opinion in drug discovery & development.

The promise and peril of chemical probes (vol 11, pg 536, 2015)

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .

TOTAL SYNTHESIS OF BREVETOXIN A : PART 2 : SECOND GENERATION STRATEGY AND CONSTRUCTION OF EFGH MODEL SYSTEM

P. A. Wallace, M. Bunnage, K. Nicolaou, 1999 .

Asymmetric synthesis of the putative structure of (-)-oryzoxymycin.

M. Bunnage, P. Steel, D. Orton, 2003, Organic letters.